Wealth Enhancement Advisory Services LLC Buys 18,797 Shares of Haleon plc (NYSE:HLN)

Wealth Enhancement Advisory Services LLC boosted its stake in Haleon plc (NYSE:HLN) by 30.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 79,813 shares of the company’s stock after purchasing an additional 18,797 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Haleon were worth $761,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its holdings in shares of Haleon by 29.8% in the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company’s stock worth $19,758,000 after acquiring an additional 475,934 shares during the period. Atria Wealth Solutions Inc. boosted its position in Haleon by 6.1% in the fourth quarter. Atria Wealth Solutions Inc. now owns 47,868 shares of the company’s stock worth $457,000 after purchasing an additional 2,758 shares during the last quarter. Savant Capital LLC grew its stake in shares of Haleon by 99.2% during the 4th quarter. Savant Capital LLC now owns 26,393 shares of the company’s stock valued at $252,000 after purchasing an additional 13,142 shares during the period. American Century Companies Inc. grew its stake in shares of Haleon by 6.1% during the 4th quarter. American Century Companies Inc. now owns 719,890 shares of the company’s stock valued at $6,868,000 after purchasing an additional 41,189 shares during the period. Finally, Entropy Technologies LP purchased a new stake in shares of Haleon during the 4th quarter valued at about $761,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Stock Down 0.0%

HLN stock opened at $10.88 on Wednesday. Haleon plc has a twelve month low of $8.25 and a twelve month high of $11.42. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock has a market cap of $48.97 billion, a P/E ratio of 31.99, a PEG ratio of 2.82 and a beta of 0.31. The business’s 50-day moving average price is $10.52 and its 200-day moving average price is $10.05.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. HSBC reiterated a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Barclays reiterated an “overweight” rating on shares of Haleon in a research note on Tuesday, May 6th. BNP Paribas Exane upgraded shares of Haleon from a “neutral” rating to an “outperform” rating and set a $13.40 price objective on the stock in a research note on Tuesday, May 27th. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. Finally, BNP Paribas upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, May 27th. Five research analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.